GlassScriptPhysician profile
Michael Tortorici
NPI 1578643961
$5,020.72
in general payments reported to CMS, 2019-2025
27 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $258 · 2021: $826 · 2022: $652 · 2023: $780 · 2024: $963 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.81 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.59 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Sun Pharmaceutical Industries INC. | $540.44 | 2019-2024 | Cequa |
| Harrow Eye, LLC | $410.97 | 2024-2025 | Vevye, Iheezo, Triesence |
| Notal Vision, INC. | $373.19 | 2021 | |
| Dompe US, INC. | $298.33 | 2021-2025 | Oxervate |
| Alcon Vision LLC | $282.86 | 2021-2025 | Rocklatan, Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $282.46 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $280.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $260.20 | 2019-2023 | |
| Oyster Point Pharma, INC. | $236.59 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $202.59 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $167.50 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $165.40 | 2020-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $120.05 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $111.86 | 2021-2024 | Tecnis Iol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $76.96 | 2025 | |
| Shire North American Group INC | $68.87 | 2019 | |
| Aerie Pharmaceuticals, INC. | $55.86 | 2020-2021 | |
| Amgen INC. | $49.27 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $48.45 | 2022-2024 | Dextenza |
| Genzyme Corporation | $41.32 | 2023 | |
| Rayner Intraocular Lenses Limited | $39.47 | 2025 | Omidria |
| Travere Therapeutics, INC. | $31.82 | 2021 | |
| Coopervision INC. | $27.78 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.87 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $20.04 | 2024 | Syfovre |
| Alimera Sciences, INC. | $16.66 | 2024 | Yutiq, Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tortorici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.